Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivoMCKEAGE, J. M; KELLAND, L. R; BOXALL, F. E et al.Cancer research (Baltimore). 1994, Vol 54, Num 15, pp 4118-4122, issn 0008-5472Article

Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamolCOLEY, H. M; JARMAN, M; BROOKS, N et al.International journal of cancer. 1996, Vol 68, Num 3, pp 356-363, issn 0020-7136Article

Pharmacology of novel steroidal inhibitors of cytochrome P450_17α (17α-hydroxylase/C17-20 lyase)BARRIE, S. E; POTTER, G. A; GODDARD, P. M et al.Journal of steroid biochemistry and molecular biology. 1994, Vol 50, Num 5-6, pp 267-273, issn 0960-0760Article

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex : In vivo activity, toxicology, and pharmacokinetics in miceRAYNAUD, F. I; BOXALL, F. E; GODDARD, P. M et al.Clinical cancer research. 1997, Vol 3, Num 11, pp 2063-2074, issn 1078-0432Article

The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenograftsCOLEY, H. M; JARMAN, M; JUDSON, I. R et al.Anticancer research. 1996, Vol 16, Num 4A, pp 1851-1856, issn 0250-7005, 5 p.Article

Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexesKELLAND, L. R; BARNARD, C. F. J; ROGERS, P. M et al.Journal of medicinal chemistry (Print). 1995, Vol 38, Num 16, pp 3016-3024, issn 0022-2623Article

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450_17α inhibitorsBARRIE, S. E; HAYNES, B. P; POTTER, G. A et al.Journal of steroid biochemistry and molecular biology. 1997, Vol 60, Num 5-6, pp 347-351, issn 0960-0760Article

Novel trans platinum complexes : Comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumoursGODDARD, P. M; ORR, R. M; VALENTI, M. R et al.Anticancer research. 1996, Vol 16, Num 1, pp 33-38, issn 0250-7005Article

Preclinical toxicology, pharmacokinetics and formulation of N², N⁴, N⁶-trihydroxymethyl-N², N⁴, N⁶-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activationRUTTY, C. J; JUDSON, I. R; ABEL, G et al.Cancer chemotherapy and pharmacology. 1986, Vol 17, Num 3, pp 251-258, issn 0344-5704Article

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activityKELLAND, L. R; BARNARD, C. F. J; MELLISH, K. J et al.Cancer research (Baltimore). 1994, Vol 54, Num 21, pp 5618-5622, issn 0008-5472Article

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV) : an orally active platinum drugKELLAND, L. R; ABEL, G; MCKEAGE, M. J et al.Cancer research (Baltimore). 1993, Vol 53, Num 11, pp 2581-2586, issn 0008-5472Article

The 5-HT₃ antagonist, BRL 443694, does not compromise the efficacy of cisplatin in tumour-bearing miceGODDARD, P. M; JONES, M; POLLARD, L. A et al.Cancer chemotherapy and pharmacology. 1990, Vol 25, Num 5, pp 177-379, issn 0344-5704, 203 p.Article

Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicityROWLANDS, M. G; PARR, I. B; MCCAGUE, R et al.Biochemical pharmacology. 1990, Vol 40, Num 2, pp 283-289, issn 0006-2952, 7 p.Article

Tumor inhibitory triazenes. III: Dealkylation within an homologous series and its relation to antitumor activityWILMAN, D. E. V; COX, P. J; GODDARD, P. M et al.Journal of medicinal chemistry (Print). 1984, Vol 27, Num 7, pp 870-874, issn 0022-2623Article